Pre-Submission Review for Infectious Disease Journals: What Reviewers Expect

Lancet Infectious Diseases is the highest-impact dedicated clinical ID journal. It wants work that could plausibly change clinical management or public-health policy, not just confirm that a known pattern also appears in one more cohort.

Editors and reviewers are usually asking:

• Is the patient population broad enough to generalize the conclusion?
• Is the primary endpoint clinically meaningful rather than merely convenient?
• Does the statistics plan support the strength of the claim being made?
• Would a clinician actually change treatment, surveillance, or counseling because of this paper?

Single-center retrospective studies can still be publishable, but they usually need more modest claims and more realistic journal targeting.

For journals such as Cell Host & Microbe, PLOS Pathogens, mBio, and Journal of Virology, the standard is different. Reviewers are not mainly asking whether the work changes immediate practice. They are asking whether the mechanistic story is complete enough to trust.

That usually means checking:

• whether the causal mechanism is shown rather than inferred
• whether genetic, biochemical, or perturbation controls close the obvious alternatives
• whether the infection model is appropriate for the claim being made
• whether the novelty still survives comparison with the recent pathogen-specific literature

In this lane, papers often get rejected not because the idea is weak, but because the mechanism is still one experiment short of feeling decisive.

Nature, Science, Cell, NEJM, JAMA, and The Lancet publish infectious-disease work only when it clears the broader-significance bar their general readership expects. That can mean a practice-changing trial, a major outbreak-relevant finding, or a mechanistic advance with very wide conceptual consequence.

This is where many teams misjudge fit. A paper can be excellent infectious-disease science and still be too narrow for a general flagship journal. Pre-submission review should make that call bluntly before the manuscript loses time in avoidable desk rejection.

Use this workflow before paying for review or before submitting:

1. Name the real journal lane first: clinical, microbiology, translational, or broad biomedical.
2. Write the one-sentence claim exactly as a skeptical editor would hear it.
3. Identify the figure, table, or analysis that most directly carries that claim.
4. Ask what the strongest reasonable reviewer objection would be in that lane.
5. Decide whether the answer requires new evidence, claim narrowing, or a different journal target.
6. Only then ask for external review or submit.

That six-step pass is what keeps teams from buying vague reassurance when the paper actually needs a fit decision.

In our pre-submission review work, infectious-disease manuscripts most often lose time when the paper sits between lanes and the authors have not decided which reviewer logic they are really asking to satisfy. A clinically framed abstract with mechanistic data, or a host-pathogen story with overclaimed bedside relevance, creates confusion immediately.

Our review of current infectious-disease author guidance supports that same pattern. Strong submissions are explicit about whether the manuscript changes practice, changes understanding, or mainly extends prior work in a narrower pathogen-specific lane. That positioning decision usually matters more than another general polishing pass.

The value is highest when the manuscript is strong enough to submit soon but the lane is still uncertain. That is common in infectious disease because many projects sit near the boundary between translational science and clinical relevance.

Pre-submission review is also worth it when:

• the paper depends on nuanced statistics or confounder handling
• the novelty claim lives or dies on very recent pathogen-specific literature
• the team is deciding between a flagship journal and a high-quality specialty title
• the revision cost of one predictable rejection would be high in time or momentum

If the manuscript is still missing core experiments, outside review is less valuable than finishing the science first.

High-value feedback in this area is concrete and lane-specific. It does not say only that the manuscript is "interesting" or "needs stronger framing." It tells you exactly which kind of reviewer objection is most likely to show up first.

For a clinical paper, that may mean hearing that the endpoint hierarchy does not support the practice claim, that the cohort is too narrow to generalize, or that the subgroup language looks more confident than the design warrants. For a host-pathogen paper, it may mean learning that one control is missing, one mechanistic step still feels inferred, or one infection model creates avoidable skepticism.

That is the standard to look for in a review:

• comments tied to the journal lane you actually want
• direct reference to which figure, analysis, or claim carries the main risk
• advice that changes submission odds, not just writing tone
• a recommendation on whether to submit now, revise first, or retarget

If the review cannot do those four things, it is probably too generic to be worth much.

The biggest delays usually come from avoidable mismatch, not from bad science. A team submits a mechanistic paper to a clinically framed journal, or a promising cohort study to a title that expects practice-changing generalizability. Then the rejection arrives exactly where a strong pre-submission pass would have predicted it.

The second time-loss pattern is claim inflation. Infectious-disease papers often sit close to public-health or translational importance, which makes it tempting to overstate consequence. Reviewers react quickly when the manuscript promises policy or practice relevance that the data package does not fully support. Fixing that after rejection is slower than narrowing the claim before first submission.

For most teams, the real outcome of pre-submission review should be one of three calls: submit now, revise first, or retarget. That is the practical standard. If the review cannot help you make one of those three decisions with more confidence and less wasted cycle time, it is not yet sharp enough.

That clarity is usually what saves the most time after rejection pressure starts.

Searchers landing here usually do not need generic advice about peer review. They need a way to understand why infectious-disease manuscripts get read through different reviewer lenses and what kind of pre-submission review actually changes submission odds.

The useful answer is not "infectious-disease journals are selective." The useful answer is what each lane will punish first and whether your manuscript is already exposed to that exact kind of criticism. That is the decision this page is meant to sharpen before submission.